Researchers have uncovered crucial insights into the changing landscape of malaria drug resistance in Burkina Faso, a country grappling with the devastating impacts of this disease. By examining the mutations in two key genes, Pfdhfr and Pfdhps, the team has shed light on how the implementation of Seasonal Malaria Chemoprevention (SMC) has influenced the evolution of drug resistance in the malaria parasite, Plasmodium falciparum. These findings hold important implications for shaping future malaria control strategies in the region.
Tracking the Malaria Resistance Landscape
Malaria remains a formidable public health challenge in many parts of the world, particularly in sub-Saharan Africa. In Burkina Faso, this disease has had a significant impact, accounting for over 55% of hospitalizations and 15% of deaths nationwide. The researchers in this study set out to understand how the introduction of Seasonal Malaria Chemoprevention (SMC) has affected the development of drug resistance in the malaria parasite.
Identifying Key Resistance Markers
The team focused on analyzing mutations in two crucial genes, Pfdhfr and Pfdhps, which are known to confer resistance to the antimalarial drugs pyrimethamine and sulfadoxine, respectively. By examining samples collected from individuals in Nanoro, Burkina Faso, before and after the implementation of SMC, the researchers were able to track the temporal trends in the prevalence of these resistance-associated mutations.
The Surge in Pyrimethamine Resistance
The study revealed a significant increase in the prevalence of mutations in the Pfdhfr gene, which is linked to resistance to pyrimethamine, following the adoption of SMC. The researchers observed a rise in the prevalence of the triple mutant Pfdhfr CIRNI from 43.6% before SMC to 89.4% after its implementation. This suggests that the widespread use of sulfadoxine-pyrimethamine, a key component of SMC, has led to the escalation of pyrimethamine resistance in the malaria parasite population.
Stability in Sulfadoxine Resistance Markers
In contrast, the prevalence of mutations associated with sulfadoxine resistance in the Pfdhps gene remained relatively stable. The researchers noted that the crucial Pfdhps K540E mutation, which can significantly impact the effectiveness of sulfadoxine, was not detected in the samples analyzed. However, they did observe an increase in the Pfdhps A437G mutation, which is also linked to sulfadoxine resistance.
Emerging Resistance Haplotypes
The study also revealed the emergence of novel Pfdhps haplotypes, such as the quintuple mutant VAGKGS, which was detected exclusively in samples collected after the implementation of SMC. The presence of these complex resistance patterns underscores the need for continuous monitoring and vigilance in the face of evolving malaria drug resistance.
Implications for Malaria Control Strategies
The findings of this study hold significant implications for the ongoing efforts to control malaria in Burkina Faso and the broader Sahel region. The observed increase in pyrimethamine resistance, coupled with the stability of sulfadoxine resistance, highlights the need to closely monitor the effectiveness of sulfadoxine-pyrimethamine in both SMC and intermittent preventive treatment during pregnancy (IPTp). As the researchers suggest, policymakers may need to consider alternative strategies, such as community-based interventions or evaluating new antimalarial drugs, to ensure the continued success of malaria control efforts in the region.
Author credit: This article is based on research by Francis Emmanuel Towanou Bohissou, Paul Sondo, Juliana Inoue, Toussaint Rouamba, Berenger Kaboré, Guétawendé Job Wilfried Nassa, A. Elisée Sié Kambou, Tiampan Edwig Traoré, Victor Asua, Steffen Borrmann, Halidou Tinto, Jana Held.
For More Related Articles Click Here
